Abstract
The median overall survival, disease-free survival and survival from disease progression of patients with progressive disease was 15, 8 months and 5 months, respectively.
22 (96%) out of 23 individuals suffering from disease progression died of the disease. The overall mortality rate was 70%.
Patients with progressive MCC spend significantly more tumour related days in the hospital compared to patients without a progressive disease.
The rate of immunosuppression was significantly higher in the MCC progressive group and those patients received more often radio- and/or chemotherapy.
Despite an aggressive therapy approach and long hospitalization, survival among patients suffering from progressive MCC was very poor. Randomized clinical trials are required to assess whether aggressive systemic and local therapy is justified in Merkel cell carcinoma patients with progressive disease.
This article is protected by copyright. All rights reserved.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.